Daix (France), October 19, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.
Daix (France), February 3, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that Dr. Nathalie Guffon (MD, Hôpital Femme-Mère-Enfant, Lyon, France), investigator of the iMProveS (improve MPS treatment) Phase IIa clinical study, will present a poster, entitled “Treatment of mucopolysaccharidosis type VI patients with odiparcil alone or in addition to enzyme replacement therapy: A Phase IIa study”, at the 16th Annual WORLDSymposium™ taking place from February 10 to 13, 2020 at the Hyatt Regency Orlando, Orlando, Florida.